Pharvaris (NASDAQ:PHVS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Pharvaris (NASDAQ:PHVS) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

PHVS has been the subject of several other research reports. Oppenheimer boosted their price target on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Leerink Partners set a $38.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Bank of America lifted their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, December 4th. Morgan Stanley increased their price objective on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.56.

Pharvaris Stock Down 2.2%

NASDAQ:PHVS opened at $25.09 on Friday. The company has a 50 day simple moving average of $25.45 and a two-hundred day simple moving average of $23.40. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.80.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. As a group, equities analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Trading of Pharvaris

Large investors have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC raised its holdings in shares of Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock worth $256,000 after acquiring an additional 447 shares in the last quarter. TD Asset Management Inc raised its stake in Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after purchasing an additional 21,388 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Pharvaris during the second quarter valued at $57,000. Geode Capital Management LLC lifted its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.